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ABSTRACT
Objective: The objective of the existing research was to develop an oral disintegrating dissolving system as one of the taste masking orodispersible 
forms together of trazodone hydrochloride tablets using direct compression technique through the use of superdisintegrants together with FlowLac, 
StarLac, and sodium starch glycolate.
Methods: The tablets were formulated using the direct compression approach. The drugs prepared have been evaluated for diverse parameters which 
include hardness, friability, weight variation, drug content uniformity, water absorption ratio, in vitro drug release, and wetting time.
Results: The hardness of all formulations from F1 to F7 proved that the tablet means thickness was nearly uniform in all formulations with the range 
of 0.520 mm–0.522 mm. Water absorption of prepared formulations was found to be 68.59%–73.21%. Bulk density, tapped density, and friability of 
the formulations were established within the limits, results of in vitro drug release study showed the drug released between 90.27% and 96.17% at 
60 min.
Conclusion: The overall study concluded that orodispersible tablets of trazodone hydrochloride have greater dissolution rate and will result in 
enhanced bioavailability. The taste masked systems are designed to provide better acceptability, improved bioavailability, for chronic patients. The 
study results revealed that the formulation F6 was contemplated as the top formulation.
Keywords: FlowLac, Orodispersible, StarLac, Trazodone hydrochloride.
INTRODUCTION TO ORAL DISPERSIBLE TABLETS
Over the past few decades, the oral drug shipping has been 
acknowledged due to the most widely applied course of management. 
The tablets are described as strong pharmaceutical dosage form 
containing drug substances with no or with additives, structured 
through compression, or molding strategies. Since part of the 
19th century, it is used widely [1]. The techniques to formulate 
the capsules are direct compression, dry granulation, and moist 
granulation [2]. At present, the demand of the development of orally 
disintegrating tablets (ODTs) is in demand because it has a full-size 
effect on the patient compliance. Those people who have swallowing 
difficulties can go oral disintegrating tablets. Dysphagia [3] is 
commonplace among all age companies and extra unique with 
pediatric, geriatric population for patients with nausea, vomiting, and 
motion sickness headaches [4]. A wide range of population accepts 
bitter pills as ODT’s due to its good taste and taste growth. Orally 
disintegrating drugs are also known as disintegrating drugs, mouth 
dissolving tablets, quick disintegrating pills, orodispersible pills, rapid 
porous pills, speedy dissolving capsules, and fast melts. They disperse 
readily in the mouth within 3 min before swallowing [5].
The special benefits of ODT’s are as follows: (i) ODTs are unit strong 
dosage forms that offer right balance, correct dosing, clean production, 
and small packaging length, and in addition to these points, patient 
handles it easily [6-9]. (ii) They may be smooth to manage for geriatric 
and pediatric patient as well as hospitalized sufferers (specifically 
for psychiatric patient and mentally retarded sufferers). (iii) The fast 
disintegration of tablet accounts for quick dissolution and the speedy 
onset of movement [10]. The bioavailability of medicine which is 
absorbed from mouth, pharynx, and esophagus is enhanced [11-13]. 
The hepatic metabolism is avoided due to pregastric absorption 
of medicine, and thereby, it decreases the dose and enhances the 
bioavailability [14].
Various strategies employed in the formulation of ODT’s encompass.
Lyophilization or freeze-drying
With the help of shape-forming additives, the solvent is removed from 
a frozen suspension or solution of the active pharmaceutical ingredient 
by a process called lyophilization. A glossy appearance of amorphous 
structure results in particularly porous and light-weight product when a 
drug is subjected to freeze-drying along with the additives. The ensuing 
tablet has dissolved right away to launch the drug, but the ODT’s 
fashioned through lyophilization has got low mechanical electricity, 
terrible stability at an elevated temperature, and humidity [15] and 
particularly freeze drier is luxurious.
Molding
Molding consists of moistening, dispersing, or dissolving the drug with 
a solvent and the prepared wet combination molded into tablets. Since 
the molded tablets have low mechanical energy, it leads to erosion and 
breakage during handling [16].
Cotton candy manner [17]
The development of a matrix of polysaccharides with the aid of the 
simultaneous act of flash melting and spinning was carried out with the 
cotton sweet technique. The candy matrix is then grinded and mixed 
with lively substances and finally compressed to ODT. Accommodation 
of high doses of the drug as well as high mechanical strength is achieved 
by this process. The use of high temperature is the limitation of this 
technique.
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Spray drying
The exceedingly, porous, high-quality powders are acquired by this 
method. The disintegration and dissolution were similarly stepped 
forward with the aid of adding effervescent agents which include citric 
acid, tartaric acid, and sodium bicarbonate. To get a porous powder, the 
formulation is subjected to spray drying. The ODT obtained from this 
approach is disintegrated much <20 s.
Mass extrusion
It is a novel technique used in application of polymer processing 
technology to prepare pharmaceutical dosage forms. This technique 
involves softening blend using the polymeric solvent along with 
cosolvent. Then, the expulsion of softened mass is done through the 
extruder or syringe to get a cylinder of the product [18].
Compaction
The ODTs are prepared using incorporating a hydrophilic waxy binder 
(notable polystrate) inside the method through soften granulation 
approach.
Phase transition process
The tablets were produced with the aid of compressing a powder 
mixture in which a two-component single-phase liquid is cooled and 
transforms into two solid phases. The tablet hardness turned into 
accelerated after the heating manner, due to the growth of interparticle 
bonds or the bonding floor region in capsules brought on through phase 
transition of lower melting factors.
Sublimation
The key factor which is responsible for the rapid disintegration of ODT 
is the existence of an extremely porous shape in the tablet. However, 
the conventional capsules contain incredibly water-soluble substances, 
they frequently fail to fall apart swiftly due to low porosity.
Three-dimensional printing (3DP)
It is a unique speedy dissolving drug delivery tool (DDD) with free 
powders in it was fabricated the usage of the 3DP procedure. By 
depending on computer-aided layout fashions, DDD containing the drug 
acetaminophen was organized robotically through 3DP machine [19]. 
Tablet undergoes fast disintegration due to the fast water penetration 
into the tablet as a consequence of the huge pore length and large 
average pore volume.
Conventional methods
The traditional methods in formulating ODT’s together with direct 
compression, dry granulation [20], and wet granulation methods using 
superdisintegrants had been adapted to provide ODT’s.
This present research presents the rationale behind the development 
of an oral fast disintegrating dissolving system is that the tablet 
disintegrates in the mouth in a fraction of minute, rapidly releases the 
drug in the stomach following oral administration. The significance of 
ODT’s is especially delivering bitter drug with ease and rapid release, 
thereby improving safety and reducing toxicity.
Trazodone is regarded as a psychoactive compound with sedative, 
anxiolytic, and antidepressant drug which is likewise described 
as having less usefulness inside the remedy of the acute phase of 
cerebral stroke. Trazodone acts as a serotonin-2 receptor antagonist, 
due to this antagonistic activity, it decreases extracellular gamma-
amino-butyric acid levels within the cerebral cortex, by blocking of 
5-hydroxytryptamine 2A receptors [21].
After oral administration, the plasma level concentration of trazodone 
hydrochloride is 2 h after single dosing when taken with food. The 
bioavailability of trazodone hydrochloride is 65% and its biological 
half-life is 5–9 h. The purpose of the prevailing investigation was to 
develop an orodispersible tablet of trazodone hydrochloride through 
direct compression approach to mask the noxious taste of trazodone 
hydrochloride.
METHODS
Trazodone hydrochloride was gifted by Aurobindo Pharma Pvt., Ltd., 
lactose (Pharmatose DCL-11) and Aerosil were gifted by M.B Chemicals, 
microcrystalline cellulose (Avicel PH 200) was procured from Simcon 
Laboratories Pvt., Ltd., sodium starch glycolate and pregelatinized 
starch from Kanwarlal Laboratories, FlowLac and StarLac from Meggle 
Pharma, and magnesium stearate was gifted from Cabot Sanmar 
Limited.
Development of standard calibration curve
Serial concentrations of trazodone hydrochloride in 0.1 N hydrochloride 
buffer (pH 1.2) having concentrations between 0 and 70 mcg/ml were 
prepared. The absorbance of the prepared solutions was measured 
spectrophotometrically at λmax 278 nm. The absorbance was plotted 
against the concentration and regression lines were calculated which 




With the aid of butter paper, a small quantity of trazodone hydrochloride 
was taken and viewed in a well-illuminated place.
Taste and odor
A very less amount of trazodone hydrochloride was used to examine the 
taste with the help of tongue and also to determine the smell.
Formulation of an orodispersible tablet of trazodone hydrochloride
Trazodone hydrochloride was prepared by direct compression 
method. A small quantity of trazodone hydrochloride was taken in a 
butter paper and considered in a well-illuminated place. A very much 
less amount of the trazodone hydrochloride was used to get the flavor 
with the help of the tongue as well as odor to get the smell. The drug 
along with polymer and other ingredient is mixed in weight proportion. 
Every ingredient (except granular directly compressible excipients) 
was passed through # 60-mesh individually. Followed by lubricating, 
the powder blends with the help of magnesium stearate (1% wt/wt) 
which was further subjected to compression into a 600 mg tablet with 
the help of flat-face spherical tooling on a single punch tablet machine 
(Table 2).
Table 1: Calibration values of trazodone hydrochloride in 0.1 N 
hydrochloric acid
S. No. The concentration of drug 
sample









Table 2: Formulation of ODT
S. No Ingredients F1 F2 F3 F4 F5 F6 F7
1. Trazodone hydrochloride 150 150 150 150 150 150 150
2. Lactose 300 - - - - - -
3. FlowLac - 176 352 402 - - 300
4. StarLac - 176 - - 432 432 -
5. Microcrystalline cellulose 102 50 50 - 80 - 102
6. Sodium starch glycolate 30 30 30 30 - 12 30
7. Aerosil 12 12 12 12 12 - 12
8. Magnesium stearate 6 6 6 6 6 6 6
Total weight in (mg) 600 600 600 600 600 600 600
ODT: Orally disintegrating tablet
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Evaluation of orodispersible tablets of trazodone hydrochloride
Evaluation parameters of pre-compressed powder
Fixed funnel method was used to determine the angle of repose. The 
funnel possessing 10 mm of an interior diameter of the stem was set at 
a height of 2 cm above the stage. The powder sample (10 g) was taken 
and gradually passed through the funnel to form a pile which touches 
the stem of the funnel. Around the pile base, a rough circle was drawn 
and radius of the formed pile was measured.
The angle of repose was determined by means of the following equation.
θ = tan-1 (h/r)
Where,
θ = angle of repose,
h = height of the pile and
r = radius of powder cone.
Bulk density
About 20 g of the sample was poured into a 100 ml graduated cylinder 
with the help of a funnel to find out the bulk densities of the granules. 
The volume in the cylinder which was occupied by the granules was 
measured and the bulk density was calculated according to the formula.
 Bulk density (g/ml) =  Weight of the sample (g)/volume 
which is occupied by the sample.
Tapped density
About 25 g of the sample was poured into the 100 ml graduated cylinder 
with the help of a funnel to find out the tapped densities of the granules. 
From the height of 2 inches, the cylinder was tapped continuously for 
getting a constant volume. After measuring the constant volume in the 
cylinder, tapped density was calculated according to the given formula.
 Tapped density (g/ml) =  Weight of sample (g)/volume 
occupied by the sample
Carr’s index
Carr’s index was analyzed using the following formula:
Carr’s index = (tapped density-bulk density)/tapped density)/100
Hausner’s ratio
The below formula was used for calculating the Hausner’s ratio of the 
granules:
• Hausner’s ratio = Tapped density/bulk density
Following are the specification for the Hausner ratios:
• Hausner ratios <1.25 indicate better flow properties
• Hausner ratios >1.25 indicate poor flow properties
Weight variation
From the formulated tablets, randomly 20 tablets were chosen and 
the average weight was estimated; then, it was evaluated with the 
individual weight of the tablet.
% deviation = Tablet weight-average weight/tablet weight×100
Friability
Roche friabilator was employed to check the friability of the tablet. 
The friabilator was operated at 100 revolutions after placing the pre-
weighed samples of tablets. The tablets were deducted and then again 
weighed.
F = W0–W/W×100
Where, W0 = Initial weight and W= Final weight.
Thickness
Vernier caliper was used to determine the thickness of the tablet. From 
every formulation, the thickness of five tablets was established.
Hardness
Tablet hardness testing is the laboratory test used to measure the 
strength of the tablet which also depends on the shape of the tablet. 
A fairly handy instrument, Monsanto hardness tester was used to 
determine the hardness of the tablet. Six tablets were determined for 
formulation F1–F7.
Disintegration time
Using digital disintegration apparatus, the disintegration time of 
six tablets from every formulation was analyzed. The temperature 
maintained in the disintegration apparatus was 37±2°°C and 900 ml 
distilled water was used to maintain the volume. In each tube, six 
tablets were introduced; then, the disc was placed and basket rack was 
placed in a 1-L beaker containing water 37±2°°C and the apparatus was 
operated for 3 min and the disintegration time in terms of seconds was 
noted.
Wetting time
The small Petri dish containing simulated saliva pH (volume −6 ml) was 
taken and a cut of tissue paper (12×10.75) was folded twice and kept on 
it (Petri dish); further, the prepared formulation was positioned on the 
paper. Total time required for the entire wetting of the tablet was noted. 
The study was performed in triplicate.
The uniform of dispersion test
Two tablets from each batch were separately kept in water (100 ml), 
and for 2 min, it was gently stirred. The depression was passed through 
22 meshes. If there is no residue on the screen, then the tablet passes 
the test.
Water absorption ratio
Water absorption ratio was determined to identify the capability of 
disintegrants to swell in the existence of water. The weight of the tablet 
after as well as before the test was determined. Using the formula, the 
water absorption ratio (R) was worked out.
R = Wb-Wa/Wa×100
Where,
Wb = Weight of the tablets after water absorption test.
Wa = Weight of the tablets before water absorption test.
Dissolution studies
With the help of USP type II apparatus, dissolution studies were carried 
out at 50 rpm. The dissolution media used for this study was 0.1 N 
hydrochloric acid. The temperature was retained at 37±2°°C. At specific 
time interval, aliquots of dissolution media were withdrawn and filtered. 
Moreover, it was restored with the same amount of fresh dissolution 
media. Further, the filtered solution was observed spectrometrically 
at 286 nm to find out the drug content. For all designed formulations, 
the dissolution study was carried and the results were compared with 
conventional and marketed tablet Apotex.
RESULTS
Preformulation studies
The data obtained for pre-compression parameters are given in Table 3. 
The values for angle of repose of every formulation (F1–F7) ranged 
from 24°°30’ to 35°°28’ which indicated the good flow property of the 
powder blend. The compressibility index and Hausner’s ratio were 
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found between 25–34.2% and 1.12–1.2 representing that the powder 
blend possesses the characteristics for direct compression. Flow 
property of powder was examined before the compression and it is 
considered as an important parameter for the content uniformity.
Evaluation of post-compression parameters
Weight variation test
Mean weight of total 20 tablets was analyzed; then, it was evaluated 
with the individual weight of the tablet. According to IP, weight of the 
tablets should lie inside the I.P limits [21]. The results are tabulated in 
Table 4.
The other post-compression parameters for trazodone hydrochloride 
orodispersible tablets by direct compression method are shown in 
Tables 5 and 6.
In vitro drug release studies of trazodone hydrochloride 
orodispersible tablets
The in vitro drug release study of formulations F1–F7 was conducted 
in 0.1 N hydrochloric acid with the pH of 1.2 for 60 min using paddle 
apparatus as shown in Table 7. It was observed that the cumulative 
percentage drug release from the F6 formulation was 96.17%. For the 
innovated formulation, the cumulative percentage drug release was 
found to be 98.56%. The promising formulation F6 was compared with 
the innovated product (Apotex 150 mg IR tablets) for the in vitro drug 
release profile.
DISCUSSION
Bulk density and tapped density of the formulation were established 
within the limits, which was helpful in stating flow property of 
the powder. From the tabulated results (Table 5), it was proved 
that the tablet means thickness was nearly uniform in all formulations 
with the range of 0.520–0.522 mm. As the amount of excipients 
increased, in the case of FlowLac, the hardness of the tablets was 
enhanced. Friability values were found to be <1% in all formulations 
and were found within the limits. The disintegration time of the tablet 
has to be optimized to develop fast disintegrating tablets. In all the 
formulations, the drug content was examined to be high (≥96.17%). 
Water absorption ratio, as well as the wetting time, is considered as an 
important criterion for understanding the capability of disintegrants 
to swell in the existence of a small quantity of water, and it was found 
to be in the range of 68.59–73.21% in 21–30 s, respectively (Table 6), 
drug release studies were conducted with 0.1 N hydrochloric acid, and 
the dissolution profile is illustrated in Table 7 and Fig. 2; the in vitro 
drug release for formulation F6 showed the better release of drug when 
compared to the marketed product (Mar) as shown in Fig. 2.
CONCLUSION
In the present study, seven formulations have been formulated, of 
which F6 showed good results. The method of preparation of tablets 
was done by simple direct compression of the drug with excipients 
followed by single-stage compression which guarantees reproducible 
batches of tablets. The results showed the influence of physicochemical 
Table 3: Evaluation of pre-compression parameters of a powder blend
S. no Parameters F1 F2 F3 F4 F5 F6 F7
1. Bulk density (g/ml) 0.472 0.541 0.524 0.451 0.428 0.469 0.578
2. Tapped density (g/ml) 0.749 0.823 0.814 0.717 0.568 0.526 0.636
3. Hausner’s ratio 1.585 1.48 1.55 1.58 1.12 1.17 1.18
4. Compressibility index (%) 36.91 32.58 35.63 37.02 29.23 31.21 30.76
5. Angle of repose 27°76’ 29°68’ 24°65’ 26°65’ 24°54’ 26°46’ 26°85’
Table 4: Weight variation test for F1–F7 formulations





F1 598–601 599.65 (-) 0.665–0.537
F2 599–603 300.45 (-) 0.582–1.007
F3 596–604 600.15 (-) 0.168–1.515
F4 597–602 599.75 (-) 1.113–0.892
F5 599–603 600.4 (-) 0.562–1.027
F6 598–603 600 (-) 0.806–1.185
F7 600–603 600.8 (-) 0.32–0.869
Table 5: Post-compression parameters for trazodone 
hydrochloride orodispersible tablets
Batch no Hardness (kg/cm2) Thickness (mm) Friability (%)
F1 2.7 5.22 0.25
F2 2.9 5.24 0.27
F3 2.6 5.21 0.25
F4 3.2 4.99 0.28
F5 3.5 4.94 0.26
F6 3.1 5.22 0.23
F7 3.6 5.21 0.29
Fig. 1: Calibration curve of trazodone hydrochloride in 0.1 N 
hydrochloric acid
Fig. 2: In vitro drug release of trazodone hydrochloride from 
various tablet formulations
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parameters on the excipients used in tablet preparation. The pre-
compression parameters comprising the angle of repose, bulk density, 
tapped density, compressibility index, and Hausner’s ratio were 
evaluated and the drug powder showed good flow properties. In the 
drug profile the formulation F6 exhibited maximum drug release 
profile when compared to the innovated product as indicated in Table 7 
and Fig. 2. Hence, the formulation F6 was contemplated as the top 
formulation and supplementary studies will be carried out for the 
profitable induction of the product.
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Table 6: Post-compression parameters for trazodone hydrochloride orodispersible tablets
Batch no Disintegration time (s) Wetting time (s) Assay (%) Water absorption ratio (%)
F1 58 30 96.56 72.51
F2 59 28 96.45 71.63
F3 58 25 97.43 69.79
F4 59 27 96.34 70.58
F5 58 24 96.24 71.31
F6 55 21 98.12 68.59
F7 57 23 96.45 73.21
Table 7: Dissolution of trazodone hydrochloride in 0.1 N hydrochloric acid of pH 1.2 from tablets of F1–F7 with the marketed product
Time (min) % CDR
F1 F2 F3 F4 F5 F6 F7 Marketed product
00 0 0 0 0 0 0 0 0
05 40.12 41.23 42.85 44.15 46.85 47.89 47.67 50.12
10 55.26 55.39 56.13 57.55 59.15 60.27 60.12 62.25
15 60.18 60.19 61.23 65.23 66.41 67.46 66.23 68.54
30 70.29 70.89 71.56 73.28 74.16 75.45 74.01 78.45
45 80.15 80.27 81.23 82.26 83.45 87.56 86.78 89.12
60 90.27 90.89 93.56 94.12 95.13 96.17 95.78 98.56
CDR: Cumulative drug release
